[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Dante Pazzanese de Cardiologia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100616852","effect-of-meditation-as-an-adjunct-to-cardiac-rehabilitation-100616852",false,"NCT07310992","Effect of Meditation as an Adjunct to Cardiac Rehabilitation","The Effect of Meditation Practice Combined With Cardiac Rehabilitation on Improving Quality of Life and Controlling Blood Pressure.","Inclusion Criteria:\n\n* Patients of both sexes, aged 18 years or older.\n* Newly enrolled in the Phase II Cardiac Rehabilitation Program.\n* Clinically stable condition with medical clearance to perform aerobic and resistance exercises.\n* Diagnosis of cardiovascular disease (e.g., coronary artery disease, post-myocardial infarction, post-cardiac surgery, or stable heart failure) warranting rehabilitation.\n* Willingness and cognitive ability to provide written informed consent.\n* Availability to attend the twice-weekly sessions for the 12-week duration of the study.\n\nExclusion Criteria:\n\n* Current regular practice of meditation, yoga, or other mind-body techniques (defined as formal practice more than once a week in the previous 3 months).\n* Current participation in other psychological or behavioral intervention clinical trials.\n* Severe cognitive impairment or psychiatric disorders that preclude understanding of the meditation instructions or group participation (e.g., dementia, untreated psychosis).\n* Unstable clinical conditions such as unstable angina, uncontrolled arrhythmias, or decompensated heart failure that contraindicate physical exercise.\n* Significant orthopedic or neurological limitations that prevent the performance of the exercise protocol.\n* Refusal to participate in the randomization process.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cardiovascular rehabilitation is a well-established standard of care that significantly reduces morbidity and mortality while improving quality of life. However, integrating behavioral interventions into physical training may offer additional benefits for autonomic regulation and emotional well-being.\n\nThis randomized clinical trial aims to investigate the efficacy of adding a brief, guided mindfulness meditation session to a standard cardiovascular rehabilitation program. The study seeks to determine whether this combined intervention enhances blood pressure control, improves perceived quality of life, and increases patient adherence compared to standard rehabilitation alone.\n\nParticipants newly enrolled in the Cardiac Rehabilitation Service will be randomized into two groups. Both groups will undergo a standard 12-week regimen of aerobic and resistance training combined with optimized medical therapy. The intervention group will additionally receive 15 minutes of voice-guided mindfulness meditation at the end of each exercise session. Key outcome measures include blood pressure variability, quality of life scores (assessed via EQ-5D), and attendance rates.",[26,27,28],"High Blood Pressure (& [Essential Hypertension])","Meditation Training","Rehabilitation Exercise","NOT_YET_RECRUITING","2025-12-30",{"date":32,"type":33},"2026-01-05","ACTUAL",{"date":35,"type":20},"2026-01-15",{"date":37,"type":20},"2028-01-15",{"name":39,"class":40},"Instituto Dante Pazzanese de Cardiologia","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100612911","rapid-management-of-resistant-hypertension-in-the-public-health-system-fast-control-100612911","NCT07259733","Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","Strategy for Rapid Control of Apparent Resistant Arterial Hypertension in the Public Health System (FAST Control)","FastControl","Inclusion Criteria: Age between 18 and 75 years;\n\nTreatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB);\n\nRecent 24-hour ambulatory blood pressure monitoring (ABPM) (\\\u003C1 month) showing values above target (24-hour BP ≥130\u002F80 mmHg);\n\nOffice blood pressure ≥140\u002F90 mmHg;\n\nPoor adherence to treatment, defined as a score ≥1 point on the Morisky Medication Adherence Scale (MMAS-4).\n\n\\-\n\nExclusion Criteria:Secondary hypertension (including hyperaldosteronism, pheochromocytoma, or renovascular hypertension);\n\nHistory of intolerance or adverse reactions to study medications, such as ACE inhibitors (cough or angioedema), thiazide or thiazide-like diuretics (electrolyte disturbances), or calcium channel blockers (significant ankle edema or headache);\n\nIndispensable use of beta-blockers or mineralocorticoid receptor antagonists;\n\nOffice blood pressure ≥ 220 × 120 mmHg;\n\nReduced left ventricular ejection fraction (LVEF \\\u003C 55%);\n\nSevere renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²);\n\nAtrial fibrillation or atrial flutter;\n\nUse of oral anticoagulants;\n\nSignificant valvular heart disease;\n\nBody mass index (BMI) ≥ 40 kg\u002Fm²;\n\nPregnant or breastfeeding women;\n\nSevere psychiatric disorders;\n\nActive malignancy with life expectancy \\\u003C 2 years;\n\n\\-","75 Years",{"count":51,"type":20},142,[23],"This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.",[55,56,57],"Apparent Resistant Hypertension","Hypertension","High Blood Pressure",[59],"Apparent resistant hypertension; Fixed-dose combination; Triple combination therapy; Perindoprile; Indapamide; Amlodipine; Clinical Trial; Brazil","RECRUITING","2025-11-21",{"date":63,"type":33},"2025-12-02",{"date":65,"type":33},"2023-07-15",{"date":67,"type":20},"2026-12-31",{"name":39,"class":40},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":69},"100568992","valvular-assessment-of-new-generation-aortic-replacement-devices-100568992","NCT06688448","Valvular Assessment of New Generation Aortic Replacement Devices","Comparative Efficacy and Durability of Next-Generation Biological Aortic Prostheses.","VANGUARD","Inclusion Criteria:\n\n* Age: 18 to 65 years.\n* Eligible for surgical replacement of native valve or re-replacement of a prosthetic valve with a bioprosthetic valve in the aortic position.\n\nExclusion Criteria:\n\n* Indicated for mechanical prosthetic valve replacement.\n* Require surgical intervention in another heart valve or transcatheter valve therapy.","65 Years",{"count":80,"type":20},200,[23],"The VANGUARD study is an open-label, prospective, randomized trial comparing the long-term outcomes of two advanced bioprosthetic aortic valves, Dafodil® and INSPIRIS Resilia®, in patients undergoing aortic valve replacement (AVR). This study aims to provide robust data on valve durability, safety, and hemodynamic performance, particularly in younger patients who may require multiple interventions over their lifetimes.",[84,85,86],"Aortic Regurgitation Disease","Aortic Valve Calcification","Bicuspid Aortic Valve Disease",[88,89,90,91,92],"aortic valve surgery","Dafodil®","Inspires Resilia®","bioprosthetic valves","aortic valve replacement","2025-01-09",{"date":95,"type":33},"2025-01-13",{"date":97,"type":33},"2024-12-01",{"date":99,"type":20},"2036-12-01",{"name":39,"class":40},""]